The Venture Codex Logo

The Venture Codex

Boehringer Ingelheim Venture Fund

Binger Strasse 173, Ingelheim am Rhein, Rheinland-Pfalz, 55216, Germany

Overview

Invests in groundbreaking therapeutics-focused biotechnology companies.

Founded

2010

Deals · 12mo

1

Links

Website

Stage focus

Seed
Series A
Series B

Geographic focus

Belgium
Germany
Switzerland
United States

Sector focus

Biotechnology
Finance
Venture Capital

Investment portfolio

9rounds
NAMEDATESIZE
STRM.BIO
Jan 2026Participated
$8 MSeed
xCures
Jun 2021Led
$13 MSeries A
Perfood
Dec 2020Led
$6 MSeries A
Aignostics
Aug 2020Led
$6 MSeed
Etherna
Jun 2020Participated
$38 MSeries B
HepaRegeniX
Jan 2020Participated
$12 MSeries B
AgomAb Therapeutics
Apr 2019Participated
$24 MSeries A
Sentien Biotechnologies
Apr 2017Led
$12 MSeries A
HepaRegeniX
Jan 2017Led
$10 MSeries A
STRM.BIO
Jan 2026Participated
$8 MSeed
xCures
Jun 2021Led
$13 MSeries A
Perfood
Dec 2020Led
$6 MSeries A
Aignostics
Aug 2020Led
$6 MSeed
Etherna
Jun 2020Participated
$38 MSeries B
HepaRegeniX
Jan 2020Participated
$12 MSeries B
AgomAb Therapeutics
Apr 2019Participated
$24 MSeries A
Sentien Biotechnologies
Apr 2017Led
$12 MSeries A
HepaRegeniX
Jan 2017Led
$10 MSeries A
9
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Boehringer Ingelheim Venture Fund: 9 funding rounds are recorded in the selected participation categories.All available history.
Boehringer Ingelheim Venture Fund: 9 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Seed11
Series A41
Series B02

Monthly Deal Activity

Boehringer Ingelheim Venture Fund: 9 deals are recorded across 118 months.All available history.
Boehringer Ingelheim Venture Fund: 9 deals are recorded across 118 months. All available history
MonthDeals
Jan '171
Feb '170
Mar '170
Apr '171
May '170
Jun '170
Jul '170
Aug '170
Sep '170
Oct '170
Nov '170
Dec '170
Jan '180
Feb '180
Mar '180
Apr '180
May '180
Jun '180
Jul '180
Aug '180
Sep '180
Oct '180
Nov '180
Dec '180
Jan '190
Feb '190
Mar '190
Apr '191
May '190
Jun '190
Jul '190
Aug '190
Sep '190
Oct '190
Nov '190
Dec '190
Jan '201
Feb '200
Mar '200
Apr '200
May '200
Jun '201
Jul '200
Aug '201
Sep '200
Oct '200
Nov '200
Dec '201
Jan '210
Feb '210
Mar '210
Apr '210
May '210
Jun '211
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '261
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Boehringer Ingelheim Venture Fund: Health & Life Sciences is the largest displayed sector by deal count (8 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Boehringer Ingelheim Venture Fund: Health & Life Sciences is the largest displayed sector by deal count (8 deals). All available history
SectorDeals
Health & Life Sciences8
AI & Machine Learning2
Networks, Cloud & Communication1
Crypto & Blockchain1
Media & Entertainment1

Deal Size Distribution

Boehringer Ingelheim Venture Fund: 9 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Boehringer Ingelheim Venture Fund: 9 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M4
$10M-$25M4
$25M-$50M1
$50M-$100M0
$100M-$250M0
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Boehringer Ingelheim Venture Fund: Europe has the largest recorded deal count among the displayed regions (6 deals).All available history.

Top 2 of 2 regions; European countries are grouped as Europe.

Boehringer Ingelheim Venture Fund: Europe has the largest recorded deal count among the displayed regions (6 deals). All available history
RegionDeals
Europe6
United States3
Boehringer Ingelheim Venture Fund: 20 co-investors are shown, with High-Tech Grunderfonds sharing 3 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Boehringer Ingelheim Venture Fund: 20 co-investors are shown, with High-Tech Grunderfonds sharing 3 recorded deals. All available history
Co-investorShared deals
High-Tech Grunderfonds3
coparion2
Advent France Biotechnology1
Ascension Ventures1
Blue Bay Capital Fund1
BNP Paribas Fortis Private Equity1
Chiesi Ventures1
Delos Capital1
EQT Life Sciences (LSP)1
Fund+1
Future Capital1
Grand Decade1
Harmonix1
IBB Ventures1
Mass Medical Angels1
MBL Venture Capital1
Metaplanet1
Mission BioCapital1
Novalis LifeSciences1
Novo Holdings1

Investment Strategy

Boehringer Ingelheim Venture Fund: Led accounts for 56% and participating for 44% of round participation.All available history.
Boehringer Ingelheim Venture Fund: Led accounts for 56% and participating for 44% of round participation. All available history
CategoryDeals (count)Share (%)
Led556%
Participating444%
Boehringer Ingelheim Venture Fund: Single-lead accounts for 60% and co-led for 40% of lead dynamics.All available history.
Boehringer Ingelheim Venture Fund: Single-lead accounts for 60% and co-led for 40% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead360%
Co-led240%

Team

Debbie Lin, PhD, MSc Eng, MPP

Executive Director

Frank Kalkbrenner

Director, Investment Manager

Ilka Wicke Dr.

Head Making more Health

Kanad Das

Investment Director, Boehringer Ingelheim Venture Fund

Knut Elbers

Project Manager

Martin Heidecker

Managing Director

Oliver Reuss

Executive Director and Investment Manager